Small cell lung cancer is fast-growing lung cancer that develops in the tissues of the lungs. It is the least common type of lung cancer and characterized by rapid, uncontrolled growth of certain cells in the lungs. Small cell lung cancer (SCLC), previously known as oat cell carcinoma, is considered distinct from other lung cancers, which are called non–small cell lung cancers (NSCLCs) because of their clinical and biologic characteristics. Small cell lung carcinoma (SCLC) arises in peribronchial locations and infiltrates the bronchial submucosa.
DelveInsight’s, “Small Cell Lung Cancer Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight
Some of Small Cell Lung Cancer Companies are:
- Ascentage Pharma
- Merck & Co
- AstraZeneca
- Advenchen Laboratories
- GlaxoSmithKline
- Advanced Accelerator Applications
- Trillium Therapeutics
- Vernalis
- Oncoceutics
- NewBio Therapeutics
- Wigen Biomedicine
- Linton Pharm
- Carrick Therapeutics
- Xencor
- Jiangsu HengRui Medicine
- Aileron Therapeutics
- Roche
- Ipsen
- Celgene
- Lee's Pharmaceutical Limited
- AbbVie
- G1 Therapeutics
- Chipscreen Biosciences
- Luye Pharma Group
- Shanghai Henlius Biotech
- CSPC ZhongQi Pharmaceutical Technology
- Impact Therapeutics
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight
DelveInsight’s Small Cell Lung Cancer report covers around 100+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Some of Small Cell Lung Cancer Therapies:
- APG-1252
- Pembrolizumab
- Olaparib
- Lucitanib
- Dostarlimab
- Lutetium-177 oxodotreotide
- Ontorpacept
- S 055746
- ONC 201
- NBT-558
- WJ-05129
- LP-003
- Samuraciclib
- XmAb18087
- SHR3162
- ALRN-6924
- Irinotecan sucrosofate
- CC-90011
- Gimatecan
- ABBV-011
- G1T28
- Chiauranib
- LY01610
- HLX10
- PLM60
- IMP4297
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight
Current Small Cell Lung Cancer Treatment Scenario and Small Cell Lung Cancer Emerging Therapies:
- How many companies are developing Small Cell Lung Cancer drugs?
- How many Small Cell Lung Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Small Cell Lung Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Small Cell Lung Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Small Cell Lung Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/small-cell-lung-cancer-pipeline-insight
Table of Contents:
Introduction
Executive Summary
Small Cell Lung Cancer: Overview
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Small Cell Lung Cancer Collaboration Deals
Late Stage Products (Phase III)
• Comparative Analysis
Pembrolizumab: Merck & Co
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Dostarlimab: GlaxoSmithKline
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
AMG 757: Amgen
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
• Comparative Analysis
S 055746: Vernalis
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Small Cell Lung Cancer Key Companies
Small Cell Lung Cancer Key Products
Small Cell Lung Cancer- Unmet Needs
Small Cell Lung Cancer- Market Drivers and Barriers
Small Cell Lung Cancer- Future Perspectives and Conclusion
Small Cell Lung Cancer Analyst Views
Small Cell Lung Cancer Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
